Inclusion Criteria:

          -  Documented histologically confirmed diagnoses of Extranodal NK/T-cell lymphoma,
             Peripheral T-cell lymphoma, Diffuse Large B-cell lymphoma (with a PD-L1 gene
             abnormality or Epstein-Barr virus positivity, or biliary tract cancer.

          -  Prior treatment:

               -  Extranodal NK/T-cell lymphoma: Must have received at least 1 previous line of
                  systemic therapy including an asparaginase-based regimen.

               -  Peripheral T-cell lymphoma: must have received at least 1 previous line of
                  systemic multi-agent chemotherapy. Participants with anaplastic large cell
                  lymphoma (ALCL) must have received brentuximab vedotin

               -  Diffuse Large B-cell lymphoma: Must have received at least 2 previous lines of
                  systemic therapy including an anti-CD20 antibody

               -  Biliary Tract Cancer: Must have received at least 1 previous line of systemic
                  therapy including gemcitabine with or without platinum

          -  Documented disease progression during or after the last therapy

          -  If not previously treated with transplant, Investigator considers the participant
             ineligible for transplant

          -  Measurable disease

          -  Adult age (as defined by respective country) at time of signing informed consent form
             (ICF)

          -  Must be able to understand the nature of the study and provide a signed and dated,
             written ICF prior to any study-specific procedures, sample collections and analyses

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1

          -  Prior radiotherapy is allowed if more than 14 days have elapsed since the end of
             treatment and radiopharmaceuticals are permitted if more than 8 weeks have elapsed
             since the end of treatment

          -  At least 14 days or 5 half-lives must have elapsed since the last chemotherapy,
             immunotherapy, biological or investigational therapy, and have recovered from
             toxicities associated with such treatment to < Grade 2

          -  Adequate hematologic, renal and hepatic function

          -  Females of childbearing potential (FCBP) must agree to use a reliable form of
             contraceptive during the study treatment period and for at least 90 days following the
             last dose of study intervention

          -  Male participants must agree to use barrier contraception (i.e., condoms) for the
             duration of the study and for at least 90 days after the last dose of study
             intervention

          -  Predicted life expectancy of at least 16 weeks

        Exclusion Criteria:

          -  Current participation in another therapeutic clinical trial

          -  Prior treatment with an anti-PD-L1 or anti-PD-1 antibody

          -  Patients with symptomatic central nervous system (CNS) metastases unless considered
             adequately treated and controlled for at least 2 weeks

          -  Prior hematopoietic stem cell transplantation

          -  History of other previous cancer that would interfere with the determination of safety
             or efficacy

          -  Any active autoimmune disease or a documented history of autoimmune disease, or
             history of syndrome that required systemic steroids or immunosuppressive medications,
             except for participants with vitiligo, hormone replacement therapy for stable thyroid
             diseases and Type 1 diabetes mellitus

          -  Apparent active or latent tuberculosis (TB) infection

          -  Seropositive for or have active infection with hepatitis C virus (HCV), unless HCV
             viral load is below the limit of quantification and participant is on concurrent viral
             suppressive therapy

          -  Seropositive for or have active viral infection with hepatitis B virus (HBV), unless
             HBV viral load is below the limit of quantification and participant is on concurrent
             viral suppressive therapy

          -  Seropositive for or active viral infection with HIV, unless the following are met:

               -  CD4+ T-cell (CD4+) counts ≥ 350 cells/uL; and

               -  Participant has been on established antiretroviral therapy (ART) for at least 4
                  weeks prior to screening and have HIV viral load < 400 copies/mL; and

               -  Participant has not had acquired immunodeficiency syndrome (AIDS)-defining
                  opportunistic infections within the past 12 months prior to screening

          -  Active infection (viral, bacterial, or fungal) requiring intravenous (IV) systemic
             therapy within 14 days

          -  Evidence of bleeding diathesis or coagulopathy.

          -  Significant proteinuria

          -  Conditions requiring chronic steroid use (> 10 mg/day of prednisone or equivalent).

          -  Recent history of attenuated viral vaccination within 30 days prior to the first dose
             of study intervention

          -  Herbal preparations/medications are not allowed throughout the treatment period unless
             first discussed with and approved by the Medical Monitor

          -  History of severe hypersensitivity reactions to other monoclonal antibodies or known
             hypersensitivity to the study intervention or its excipients.

          -  Known current drug or alcohol abuse

          -  Major surgical procedures ≤ 28 days prior to the first dose of study intervention, or
             minor surgical procedures ≤7 days prior to the first dose of study intervention

          -  Pregnant or lactating

          -  Any of the following cardiac diseases currently or within the last 6 months:

               -  QT interval corrected using Fridericia's formula >450 milliseconds in men and >
                  470 milliseconds in women (up to 480 milliseconds may be allowed after discussion
                  between the Investigator and the Medical Monitor).

               -  Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple Gated
                  acquisition (MUGA) scan or echocardiogram (ECHO)

               -  Unstable angina pectoris

               -  Congestive heart failure (New York Heart Association ≥ Grade 2)

               -  Acute myocardial infarction

               -  Clinically significant conduction abnormality not controlled with pacemaker or
                  medication

               -  Significant ventricular or supraventricular arrhythmias (Participants with
                  chronic rate-controlled atrial fibrillation in the absence of other cardiac
                  abnormalities are eligible.)

          -  Underlying medical conditions that, in the opinion of the investigator and/or medical
             monitor, will render the administration of study drug hazardous or obscure the
             interpretation of safety or efficacy results